Clinical trials: Tamsulosin
Healthy
CKD-397 Drug-drug Interaction Study (A)
The purpose of this study is to investigate to effect of tamsulosin on the pharmacokinetic properties of tadalafil
- Trial name
- CKD-397DDI(A) (NCT02247518)
- Testing
- Cialis Tab. 5mg, Harnal-D Cap. 0.2mg
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
- Trial name
- NCT02072213
- Testing
- GL2702 GLARS-NF1, Omix Ocas
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Postoperative Urinary Retention
Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
Double blinded, randomized controlled prospective study looking at 2 preoperative doses of Tamsulosin an alpha-adrenergic blocker in preventing post-operative urinary retention.
- Trial name
- NCT02958878
- Testing
- Tamsulosin
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Ascension Health
Prostatic Hyperplasia
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia
- Trial name
- NCT02245555
- Testing
- Tamsulosin
- Volunteers
- 1,060 people
- Sponsor
- Boehringer Ingelheim
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
Benign Prostatic Hyperplasia
Study to Compare the Safety and Pharmacokinetics of CKD-397
The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.
- Trial name
- CKD-397 (NCT02645890)
- Testing
- CKD-397, TD+TM
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Prostatic Hyperplasia
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).
- Trial name
- NCT02245503
- Testing
- Tamsulosin
- Volunteers
- 7,391 people
- Sponsor
- Boehringer Ingelheim
Urinary Tract Diseases
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.
- Trial name
- NCT00239265
- Testing
- Tamuslosin
- Where
- 6 sites in Japan
- Sponsor
- Astellas Pharma Inc
Urological Manifestations
Actual Use Study of Tamsulosin in Men
An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before…
- Trial name
- NCT02573311
- Testing
- tamsulosin hydrochloride
- Where
- 40 sites in United States
- Volunteers
- 1,117 people
- Sponsor
- Boehringer Ingelheim
Urinary Incontinence
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
- Trial name
- VICTOR (NCT00333112)
- Testing
- solifenacin succinate, tamsulosin
- Where
- 74 sites in United States
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Inc
EC905, Pharmacokinetics
A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)
Tamsulosin (sold under the name Omnic OCAS) is used for treatment of voiding complaints related to an enlarged prostate. Solifenacin (sold under the name Vesicare) is used for the treatment of patients suffering from problems…
- Conditions
- EC905, Pharmacokinetics, Multiple Dose, Healthy Subjects
- Trial name
- NCT01953848
- Testing
- EC905
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healty Male Volunteers
CKD-397 Drug-drug Interaction Study (B)
The purpose of this study is to investigate to effect of tadalafil on the pharmacokinetic properies of tamsulosin
- Trial name
- CKD-397DDI(B) (NCT02247505)
- Testing
- Harnal-D Cap. 0.2mg, Cialis Tab. 5mg
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Benign Prostatic Hyperplasia
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
- Trial name
- NCT00379067
- Testing
- Tamsulosin OCAS
- Volunteers
- 882 people
- Sponsor
- Astellas Pharma Inc
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).
- Trial name
- NCT00507455
- Testing
- solifenacin succinate, tamsulosin hydrochloride
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 222 people
- Sponsor
- Astellas Pharma Inc
Urologic Diseases
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State
The purpose of this study is to assess the bioequivalence of the second generation dutasteride and tamsulosin hydrochloride (HCL) combination capsule versus currently available commercial combination of dutasteride 0.5 milligram…
- Trial name
- NCT02052713
- Testing
- Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg, Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia
Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in patients with signs and symptoms of benign prostatic hyperplasia (BPH).
- Trial name
- NCT02244242
- Testing
- Tamsulosin hydrochloride
- Volunteers
- 493 people
- Sponsor
- Boehringer Ingelheim